RT Journal Article
SR Electronic
T1 Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient
JF BMJ Case Reports
FD BMJ Publishing Group Ltd
SP bcr2012007995
DO 10.1136/bcr-2012-007995
VO 2013
A1 Ola Abbas
A1 Ali Shamseddin
A1 Sally Temraz
A1 Ali Haydar
YR 2013
UL http://casereports.bmj.com/content/2013/bcr-2012-007995.abstract
AB Posterior reversible encephalopathy syndrome (PRES) is a neurological disorder characterised by distinct radiological features. Common precipitants of this disorder include acute medical illness, hypertensive crisis, eclampsia, immunosuppressive therapy and chemotherapy. We present the case of a patient with advanced ovarian carcinoma who developed PRES shortly after receiving bevacizumab (Avastin), an inhibitor of vascular endothelial growth factor. The patient's medical history and clinical presentation both suggest bevacizumab as the precipitator for PRES. This agent has been often overlooked as a possible cause of this rare neurological syndrome.